Key Takeaways
- Competitive bidding can increase your dental practice sale price by 15–40% compared to accepting a single unsolicited DSO offer.
- Without a structured auction, sellers often leave $150,000–$300,000 on the table per $1 million of headline sale price.
- Diligence-grade financials and a complete data room before going to market help prevent price cuts during buyer due diligence.
- Evaluating offers requires comparing guaranteed cash, rollover equity, earnout terms, and tax treatment, not just headline EBITDA multiples.
- McLerran & Associates can help you run a competitive process and explore your options, so you understand your practice’s potential value.
Why A Competitive Process Matters For Dental Practice Owners
The information gap between a practice owner and a DSO buyer can be significant. DSO acquisition teams review deals every week. They know current market multiples, typical structures, and where most owners will compromise. A solo owner negotiating with one DSO usually faces a steep learning curve.
The financial impact of that gap is measurable. Running a competitive process can add 15–40% to the headline price and 25–60% to net after-tax proceeds compared to accepting a first inbound DSO offer. McLerran & Associates’ clients typically receive around 10 offers per listing, which creates competitive tension around both price and terms.
Close rates tell a similar story. Do-it-yourself sales close at roughly 15–20%, while a well-run brokered process closes at approximately 80%, based on McLerran & Associates’ experience across roughly 2,000 completed transactions. The difference comes down to process, preparation, and professional representation.
A competitive process changes three core elements of your outcome:
- Price: Multiple buyers bidding against each other move offers toward fair market value instead of a single buyer’s preferred anchor.
- Terms: Cash at close, earnout structure, and equity terms become more flexible when you can credibly choose another offer.
- Leverage: A seller with 10 offers negotiates from a very different position than a seller with one letter of intent.
Step 1: Prepare Diligence-Grade Financials Before You Go To Market
Get A CPA-Led EBITDA Analysis With Proper Add-Backs
EBITDA, or Earnings Before Interest, Taxes, Depreciation, and Amortization, is the core metric DSOs use to value your practice. A weak or unsupported EBITDA analysis often gets challenged, revised downward, and used to justify a price reduction during due diligence. Buyers refer to this as “re-trading.”
A diligence-grade valuation, prepared by a CPA with dental-specific M&A experience, sets a clear narrative around your profitability before buyers try to define it for you. McLerran & Associates builds every engagement on a comprehensive, CPA-led EBITDA analysis that is designed to hold up when buyers scrutinize it. Aggressive or unsupportable add-backs are a common reason a deal drops in price during due diligence, and buyers’ quality-of-earnings reviews can strip out $200,000–$400,000 if reported EBITDA is inflated.
Clean Up Your Books And Document Discretionary Expenses
Add-backs are legitimate personal or non-recurring expenses that run through the business and are added back to profit to calculate true EBITDA. Common examples include owner compensation above a market clinical rate, personal expenses run through the practice, above-market rent paid to an owner-controlled real estate entity, and one-time legal or consulting fees. Each item needs clear support.
Buyers will review three to five years of financial records, so every add-back should be documented and defensible.
Build Your Marketing Profile And Data Room
A data room is a secure, organized folder of everything a buyer needs to evaluate your practice. Buyers typically expect to see:
- Three to five years of tax returns and profit-and-loss statements
- Production and collections reports by provider and procedure code
- Patient demographics and active patient count
- Payer mix, meaning revenue by insurance type and fee-for-service
- Staff roster and compensation details
- Facility lease terms and renewal options
- Equipment inventory and maintenance records
If you are unsure how your current records compare to these expectations, McLerran & Associates can review your situation and outline next steps.
Step 2: Build Your Buyer List And Understand DSO Types
A competitive process usually involves a targeted group of qualified buyers that can submit multiple offers. Quality matters more than raw volume. A strong buyer list is vetted for financial backing, acquisition track record, and reputation among dentists who have already sold to them. Poorly run or undercapitalized DSOs should be excluded entirely, because as much as 40% of a DSO deal can be paid in equity rather than cash, and buyer quality affects that equity outcome.
To vet effectively, it helps to understand the buyer landscape. Buyers generally fall into two categories: strategic buyers, which are DSOs adding your practice to existing infrastructure, and financial buyers, which are private equity firms or family offices, including those seeking a platform acquisition. Both categories can fit, depending on your practice’s size, specialty, and structure.
Markets with fewer than three candidate DSOs in a region or specialty can limit competitive uplift, which makes national buyer relationships valuable. McLerran & Associates maintains a large vetted buyer pool in the dental M&A market and has blacklisted DSOs known for poor post-close environments, so the buyers who reach your table are pre-qualified.
Step 3: Run The Auction With A Structured Timeline
A clear timeline helps build competitive tension while protecting your leverage. McLerran & Associates’ active bid process typically runs 45–60 days, within a total engagement of 6–10 months from preparation through closing. The sequence below reflects that active bid window and shows how each phase builds momentum.
- Weeks 1–2: Finalize diligence-grade financials, EBITDA analysis, and marketing materials.
- Weeks 3–4: Contact vetted buyers and distribute a confidential teaser, which is a brief anonymized summary of the practice, under non-disclosure agreements.
- Weeks 5–6: Receive initial indications of interest (IOIs). These are non-binding preliminary offers that outline a valuation range and deal structure.
- Weeks 7–8: Share detailed information with qualified buyers and schedule management meetings or practice tours.
- Weeks 9–10: Receive final offers, including proposed price, structure, and key terms.
- Weeks 11–12: Negotiate the letter of intent (LOI), which is the non-binding document that sets the framework for the deal, and select the preferred bidder.
A controlled auction differs from an open bidding war. A controlled process maintains confidentiality, preserves leverage by signaling competition without naming other bidders, and usually produces better outcomes than informal outreach to several buyers. Verbal concessions made on introductory calls can become anchors in formal negotiations, so a deliberate process for every buyer interaction matters.
Step 4: Evaluate Offers Beyond The Headline EBITDA Multiple
The EBITDA multiple, meaning the number used to multiply your adjusted EBITDA to reach a purchase price, is the most visible figure in a DSO offer, but it is not the most important one. Sellers benefit from comparing offers on both immediate guaranteed cash and the terms of contingent upside, because the advertised total value often blends guaranteed and future components.
A typical DSO deal structure can include several parts:
- Cash at close: The guaranteed upfront payment, often 60–75% of total deal value. This portion is certain at signing.
- Rollover equity: Ownership retained in the DSO’s parent company, often called the “second bite of the apple.” This equity is illiquid and converts to cash only at a future recapitalization or sale, which may be three to seven years away and is not guaranteed. Equity can sit at the joint-venture level, tied to your specific practice, or at the holding-company level, tied to the broader platform, and each structure carries different risk and upside.
- Earnout: Additional payments that depend on the practice hitting post-close performance targets, usually over one to three years. Earnout risk largely sits with the seller because the buyer controls operations after closing.
McLerran & Associates prepares multi-year, multi-structure financial forecasts for each client. These models show real after-tax proceeds across deal structures and time horizons, so you can compare offers on an apples-to-apples basis instead of relying on headline multiples alone.
Tax treatment also varies by component. Goodwill is generally taxed at long-term capital gains rates, while compensation and non-compete payments are typically taxed as ordinary income. This distinction can shift tens of thousands of dollars in after-tax proceeds, depending on how the purchase price is allocated. A qualified tax advisor can help you evaluate your specific situation.
Step 5: Avoid Common Pitfalls That Kill Deals
Pitfall 1: Accepting A “Free” Valuation That Anchors The Price Low
A free valuation usually serves as a lead-generation tool rather than a defensible financial analysis. Once a low number appears, it often becomes the anchor for every later negotiation. McLerran & Associates’ CPA-led valuation is completed before going to market, so the number is designed to hold when buyers test it.
In one engagement, a free valuation estimated a practice at $2.5 million. McLerran valued the same practice at $4.5 million, and it ultimately sold for $5.25 million after a competitive process.
Pitfall 2: Negotiating With Only One DSO
A first offer from a DSO usually sets a low anchor rather than fair market value. Many dental owners accept the first unsolicited DSO offer and later learn that a competitive process could have paid them 20–40% more. Creating real competition is one of the most effective tools available to a seller.
Pitfall 3: Overlooking Buyer Quality
The highest bidder does not always provide the best long-term outcome. Rollover equity results have ranged from 2x–5x on rollover dollars in successful DSO exits to write-downs or delayed liquidity when platforms underperform. Vetting buyers for financial stability, management quality, and track record with acquired practices can be as important as negotiating the headline price.
Pitfall 4: Accepting Poor Earnout Terms
Some DSO purchase agreements include earnout definitions that are very difficult to achieve, often buried in schedules attached to separate documents. Non-punitive earnout terms, such as pro-rata provisions that pay a proportional amount for a near-miss on a target or a later start date to account for integration disruption, work best when negotiated into the LOI rather than left for the purchase agreement.
Pitfall 5: Allowing The Deal To Re-Trade During Diligence
Re-trading occurs when a buyer uses the due diligence process to justify a price reduction after the LOI is signed. During exclusive due diligence, 10–25% multiple compression is common if diligence surprises appear. A quality-of-earnings defense, meaning a sell-side advisor who can respond to buyer challenges with documented EBITDA support, is a primary protection against this risk.
McLerran & Associates reports a transaction rate of approximately 85–90%, compared to an industry norm closer to 35–40%. Diligence-stage advocacy and preparation contribute significantly to that difference.
The Role Of A Sell-Side Advisor In A DSO Sale
A sell-side advisor works exclusively for the practice owner. That alignment matters because every decision in the process, from which buyers to contact to how to respond to a re-trade attempt, can affect your outcome. A dental-specific advisor brings a vetted national buyer pool, diligence-grade financial work product, and negotiating leverage built from running many similar transactions each year.
McLerran & Associates has completed approximately 2,000 practice sales, representing roughly $2 billion in closed transaction volume, and has evaluated more than 10,000 practices. The team brings over 100 years of collective dental-industry experience as former investment bankers, practice-finance lenders, DSO buyers, CPAs, and advisors. That depth helps the firm read specialty and market dynamics that a generalist may miss, and DSO buyers often bid more aggressively on McLerran listings because they know the work product is credible.
McLerran & Associates operates nationally, with offices in Cleveland (led by Justin Klingshim), Atlanta (led by Matt Sutton), Northern Virginia (led by Andrew Kobylski), Los Angeles (led by Steven Au), and Phoenix (led by Brian Carroll, covering the Mountain West). Practice owners who are considering a transition, whether soon or several years out, can speak with the team to explore timing and strategy.
Frequently Asked Questions
How Much More Can I Get With Competitive Bidding?
Based on McLerran & Associates’ experience across roughly 2,000 completed transactions, a structured competitive bid process can increase your practice’s sale price by roughly the 15–40% uplift mentioned earlier compared to accepting a single unsolicited offer. The additional value comes from price competition among multiple buyers and from the leverage that comes with being able to walk away from any single offer. Sellers who work with a professional advisor often see further improvement, reflecting the advisor’s sourcing access, buyer relationships, and negotiation experience.
How Many DSOs Should I Approach?
A well-run competitive process usually relies on approaching a targeted group of qualified buyers rather than contacting every possible DSO. Quality matters more than volume. Each buyer should be vetted for financial backing, acquisition track record, and reputation, and weaker buyers should be screened out.
In markets with fewer than three viable DSO candidates, the competitive dynamic can be structurally limited, which makes national relationships and a large vetted pool meaningful advantages.
What Is A Typical DSO EBITDA Multiple?
EBITDA multiples in dental practice sales vary by practice size, specialty, number of locations, and market conditions. Smaller solo general practices tend to attract lower multiples, while multi-location groups and specialty practices often command higher ranges.
Specialty practices such as oral and maxillofacial surgery, orthodontics, and pediatric dentistry can earn a premium of one to three additional turns of EBITDA over comparable general dentistry practices. Platform-grade groups with substantial EBITDA and multiple locations can reach the upper end of the market.
These figures represent ranges rather than guarantees. Your specific multiple depends on fundamentals such as payer mix, provider concentration, lease terms, and the competitive dynamics of your buyer process. A comprehensive, CPA-led valuation remains the most reliable way to understand where your practice fits.
How Do I Compare Offers With Different Structures?
The headline EBITDA multiple provides a starting point, but it does not tell the full story. To compare offers accurately, you can model the risk-adjusted, after-tax value of each component separately. These components include guaranteed cash at close, rollover equity adjusted for illiquidity and platform risk, earnout payments adjusted for the likelihood of achievement, and the economic cost of any post-close employment commitment at below-market compensation.
Tax treatment also varies by component. Goodwill is generally taxed at long-term capital gains rates, while compensation and non-compete payments are typically taxed as ordinary income. McLerran & Associates prepares multi-year financial forecasts across deal structures and time horizons so clients can compare real after-tax proceeds instead of relying on headline numbers. A qualified tax advisor can help with the specifics of your situation.
What Happens If The Buyer Tries To Renegotiate During Diligence?
Re-trading, which occurs when a buyer uses the due diligence process to seek a price reduction after the LOI is signed, is a known pattern in dental practice M&A. The main protection is a diligence-grade EBITDA analysis prepared before going to market, so every add-back is documented and defensible when the buyer’s quality-of-earnings team reviews it.
A sell-side advisor who can respond to buyer challenges with credible financial work and who can remind buyers that other vetted bidders exist can deter many re-trade attempts. The 85–90% transaction rate mentioned earlier reflects McLerran & Associates’ ability to defend valuations through diligence and keep deals on track.
How Long Does The Process Take?
McLerran & Associates’ active bid process, from buyer outreach through LOI selection, typically runs 45–60 days. The full engagement, from initial preparation through closing, usually spans 6–10 months.
Compressing the process below that window often reduces valuation, because buyers have less time to compete and sellers have less leverage. Preparation work completed before going to market, such as financial normalization, data room assembly, and EBITDA analysis, can keep the active phase efficient while still supporting a strong outcome.
